Home
Team
Russell Hirsch
David Schnell
Alex Barkas, In Memoriam
About
What We Do
What We've Achieved
Contact
Portfolio
News

Prospect Venture Partners

Home
Team
Russell Hirsch
David Schnell
Alex Barkas, In Memoriam
About
What We Do
What We've Achieved
Contact
Portfolio
News
David Schnell
February 3, 2020

February 3, 2020 - Insmed Announces Positive Top-Line Results from Phase 2 WILLOW Study of INS1007 in Patients with Non-Cystic Fibrosis Bronchiectasis

David Schnell
February 3, 2020

Source:https://investor.insmed.com/2020-02-03-Insmed-Announces-Positive-Top-Line-Results-from-Phase-2-WILLOW-Study-of-INS1007-in-Patients-with-Non-Cystic-Fibrosis-Bronchiectasis

Newer PostFebruary 11, 2020 - NGM Bio Announces Initiation of Phase 1a/1b Clinical Study of NGM120 for the Potential Treatment of Cancer and Cancer Anorexia/Cachexia Syndrome (CACS)
Older PostJanuary 7, 2020 - AtriCure Announces Successful Completion of Patient Enrollment of aMAZE Clinical Trial and FDA Approval of Continued Access Protocol

Contact Prospect
Venture Partners:

Address:
525 University Ave., Suite 1350
Palo Alto, CA 94301

Phone:
(650) 327-8800

Prospect Ventures Funds:
Prospect Venture Partners I
Prospect Venture Partners II
Prospect Venture Partners III

 Connect with Prospect Ventures:
 Prospect Ventures on LinkedIn
 Prospect Ventures on Crunchbase
 Prospect Ventures on Bloomberg
 Prospect Ventures on CB Insights
 Prospect Ventures on Palico
 Prospect Ventures on Index.co
 Prospect Bio Ventures

Back to Top

© 2018 - Prospect Venture Partners.. All Rights Reserved
No content on this site may be republished or reprinted without written permission from Prospect Venture Partners